Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He was a co-founder of Bedrocan Canada, one of Canada’s first licensed producers of medical cannabis, and founding chairman of the Cannabis Canada Association, a trade group with 17 licensed producers. Mr. Wayne also was instrumental in developing the Canadian Consortium for the Investigation of Cannabinoids, a global innovator in education and research on medical cannabis. In this interview with BioTuesdays.com, Mr. Wayne discusses the potential of cannabis-based treatments and how they can offer alternatives to traditional medicines, avoid negative side effects and be disruptive to the pharmaceuticals sector.

Read More

Medicenna targeting brain cancer with molecular Trojan horse

Medicenna targeting brain cancer with molecular Trojan horse

Medicenna Therapeutics (TSXV:MDNA) is advancing a targeted dual-action immunotherapeutic, MDNA55, that consists of an engineered version of interleukin-4 (IL-4) plus a tumor-killing cytotoxin for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.

Read More

In conversation with Thomas Ronk of Buyins.net

In conversation with Thomas Ronk of Buyins.net

As the founder and CEO of Buyins.net, Thomas Ronk has created a proprietary database and trading strategy based on short sale timing and sales data that was not accessible to anyone prior to January 2005. As a registered representative of Transamerica Financial Resources, a division of Transamerica, Mr. Ronk managed more than $150-million in equity accounts from 1993 until 1998. He has 27 years of trading experience and is the principal of Century Pacific Investments, a registered investment advisor in California. Prior to the investment business, Mr. Ronk studied Electrical Engineering and Computer Science at the University of California at San Diego. In this interview with BioTuesdays, Mr. Ronk discusses manipulative short selling and how his company helps clients to analyze and develop a plan to deal with it.

Read More

IntelGenx has multi-faceted BD approach for its oral films

IntelGenx has multi-faceted BD approach for its oral films

With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing opportunities, and continuing to build its product pipeline jointly with R&D.

Read More

​​​​​​​In conversation with Yijun Huang

​​​​​​​In conversation with Yijun Huang

As a co-founder and chief technical officer of closely held EyeKor, which helps clients navigate the ever-changing landscape of ophthalmic clinical trials, Dr. Yijun Huang, a bioengineering executive, cut his teeth developing software and hardware solutions for ophthalmic imaging applications, both in academic and industrial situations. They include VP of engineering at Topcon Medical Systems, a major Japanese manufacturer of ophthalmic devices. He was also a member of Fundus Photograph Reading Center at the University of Wisconsin-Madison, which acts as a central imaging lab collecting and interpreting images from various ophthalmic clinical trials. In this interview with BioTuesdays.com, Dr. Huang discusses EyeKor’s Excelsior software platform for imaging data management, its market penetration and a recent collaboration with Clearside Biomedical (NASDAQ:CLSD).

Read More

3DS’ genomic imaging for precision medicine

3DS’ genomic imaging for precision medicine

As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging software, known as TeloView, goes beyond identifying whether a patient suffers from a specific condition. By analyzing a patient’s chromosomal arrangement, or signature, TeloView can help doctors tailor personalized treatment and manage each individual patient. With two decades of executive life sciences management and start-up experience, including successive roles at Bayer and J&J, Mr. Flowerday’s mission at 3DS is to transform a highly promising platform technology into a commercial reality with U.S. partners, focus on those tests that can deliver early value and broaden the company’s development program. In this interview with BioTuesdays.com, Mr. Flowerday discusses recent advances in 3DS’ lead diagnostic programs and their application to drug development.

Read More

Titan’s next ProNeura-based implant dovetails with PD awareness month

Titan’s next ProNeura-based implant dovetails with PD awareness month

After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to develop an implant to treat Parkinson’s disease.

Read More

Checkpoint targeting registration studies by end of 2018

Checkpoint targeting registration studies by end of 2018

Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and lead immuno-oncology (IO) agent, CK-301.

Read More

Histogenics to complete Phase 3 enrollment in Q2

Histogenics to complete Phase 3 enrollment in Q2

Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee cartilage regeneration.

Read More

Arch moving to regulatory stage this year

Arch moving to regulatory stage this year

Arch Therapeutics (OTCQB:ARTH) has multiple regulatory filings planned in the U.S. and Europe this year for its AC5 Topical Hemostatic Device as the biopharma company shifts to regulatory-stage footing ahead of commercialization.

Read More

Jaguar, Napo merger set for transformative growth

Jaguar, Napo merger set for transformative growth

The proposed merger of Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals is expected to create a combined company with prescription product revenue, potential line extensions and an expanded pipeline.

Read More

Kalytera cannabidiol platform to target GvHD

Kalytera cannabidiol platform to target GvHD

Kalytera Therapeutics (TSX-V:KALY) has put its bone repair and osteoporosis research programs on the back burner in order to focus development of a new cannabidiol (CBD) therapeutic for the treatment of acute Graft versus Host Disease (GvHD).

Read More

In conversation with Chiara Russo

In conversation with Chiara Russo

As a specialty pharmaceuticals analyst with Cantor Fitzgerald for the past 2 1/2 years, Chiara Russo covers developmental-stage companies that are on the cusp of changing the medical landscape as we know it. A philosophy major with an MBA from the Olin School of Business at Babson College, Ms. Russo was a R&D innovation consultant for Cubist Pharmaceuticals before becoming a sell-side equity research analyst. On the Street, she has been a research associate at ThinkEquity and VP and specialty pharmaceuticals analyst at Janney Montgomery Scott. In this interview with BioTuesdays.com, Ms. Russo discusses industry trends and some of the stocks she likes.

Read More